These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 22383396)

  • 1. Type 2 diabetes in pediatrics and adults: thoughts from a clinical pharmacology perspective.
    Vaidyanathan J; Choe S; Sahajwalla CG
    J Pharm Sci; 2012 May; 101(5):1659-71. PubMed ID: 22383396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevalence of diabetes, antidiabetic treatment and chronic diabetic complications reported by general practitioners].
    Fabian W; Majkowska L; Stefański A; Moleda P
    Przegl Lek; 2005; 62(4):201-5. PubMed ID: 16229234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Could oral antidiabetic agents be useful in the management of different types of diabetes and syndromes of insulin resistance in children and adolescents?].
    Otto-Buczkowska E; Nowowiejska B; Jarosz-Chobot P; Stańczyk J
    Przegl Lek; 2009; 66(7):388-93. PubMed ID: 20043582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus].
    Ozawa H; Murai Y; Ozawa T
    Yakushigaku Zasshi; 2003; 38(1):11-27. PubMed ID: 14570054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antidiabetic agents in pregnancy and lactation: a paradigm shift?
    Feig DS; Briggs GG; Koren G
    Ann Pharmacother; 2007 Jul; 41(7):1174-80. PubMed ID: 17535842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients.
    Shukla UA; Chi EM; Lehr KH
    Ann Pharmacother; 2004 Jan; 38(1):30-5. PubMed ID: 14742789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diabetes mellitus under 30 years of age. Results of 18 years experience with oral treatment (author's transl)].
    Mirouze J; Cartry E
    Diabete Metab; 1975 Jun; 1(2):113-8. PubMed ID: 1234068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.
    Panicker GK; Karnad DR; Salvi V; Kothari S
    J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes.
    Howlett H; Porte F; Allavoine T; Kuhn T; Nicholson G
    Curr Med Res Opin; 2003; 19(3):218-25. PubMed ID: 12803736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy.
    Brown DL; Brillon D
    J Natl Med Assoc; 1999 Jul; 91(7):389-95. PubMed ID: 10643211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral hypoglycemic agents in type II diabetes mellitus.
    Lubbos H; Miller JL; Rose LI
    Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
    González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ
    J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
    Savage S; Estacio RO; Jeffers B; Schrier RW
    Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.
    Hung YC; Lin CC; Wang TY; Chang MP; Sung FC; Chen CC
    Diabetes Metab Res Rev; 2013 Nov; 29(8):673-9. PubMed ID: 23956007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New clinical data with metformin therapy in patients with diabetes mellitus].
    Jermendy G
    Orv Hetil; 2010 Dec; 151(49):2025-30. PubMed ID: 21106483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric drug development programs for type 2 diabetes: A review.
    Christensen ML; Franklin BE; Momper JD; Reed MD
    J Clin Pharmacol; 2015 Jul; 55(7):731-8. PubMed ID: 25781151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.